Background: In musculoskeletal sarcomas, brainmetastases are rare, butseverely affectquality of life. Methods: All patients with musculoskeletal sarcomas who were treated at our institutions from 1975 to 1997were reviewed for examples of brain metastasis. Results: Of 480 sarcoma patients, 179 had distant metastases, including 20 patients with brain metastases (4.2%). Alveolar soft part sarcoma (3/4), extraskeletal Ewing's sarcoma (2/8), rhabdomyosarcoma (2/13) and bone Ewing's sarcoma (2/18) tended to metastasize to the brain. All 20 patients had distantor local relapses and 16 of the 20 patients had pulmonary metastases. Three patients underwent surgical treatment and two of them survived over 1 year. Meansurvival after diagnosis of brain metastasis was 5.1 months. Conclusions: Patients with alveolar soft part sarcoma, Ewing's sarcoma, rhabdomyosarcoma and pulmonary metastases have a high risk of brain metastasis.
INTRODUCTION
Brain metastasis from musculoskeletal sarcoma is apparently very rare. The true incidence, clinical characteristics and prognosis in various histological subtypes are not well known. Systemic chemotherapy has prolonged the survival of sarcoma patients.but may result in an increased incidence of intracranial metastases because of poor blood-brain barrier penetration of the chemotherapeutic agents (l) . The aim of this report is to clarify the incidence, histological types and prognosis in sarcoma patients with brain metastases. We present the clinical characteristics of 20 such patients.
PATIENTS AND METHODS
The records of patients with musculoskeletal sarcomas treated at our institutions, who were followed up for at least 1 year, between 
RESULTS
Of 480 patients with musculoskeletal sarcomas, 20 developed symptomatic brain metastases (4.2% of all sarcoma cases, 11.2% of cases with distant metastases). Alveolar soft part sarcoma (3/4), extraskeletal Ewing's sarcoma (2/8), rhabdomyosarcoma (2/13) and bone Ewing 'ssarcoma (2/18) tended to show relatively high incidences of brain metastases (Table 1) . Table 2 summarizes the clinical features of 20 patients with brain metastases. Age at diagnosis of brain metastasis ranged from 7 to 66 years. The interval between initial treatment of primary tumor and brain metastases ranged from 0 to 180 months (mean, 36 months). Presenting symptoms were headache in 10 cases, general convulsion in three cases and loss of consciousness, facial spasm, dementia, hemiplegia, visual disturbance, nausea and facial palsy in one case each. The locations of brain metastases were confirmed by computed tomography in 19 cases and by autopsy in one case. Twelve patients had solitary lesions and eight patients had multiple lesions. Lung metastasis occurred in 16 patients (80%), four of which were synchronous and 15 metachronous with brain lesion. The time to brain metastases after lung metastases varied from 0 to 120 months. Although four patients had no lung metastasis, three of these patients had distant metastases in locations other than the lung (bone, soft tissue, retroperitoneal space). One patient had only brain metastasis. This patient had MPH of the axilla with four local recurrences (case 5).
Three patients underwent resection of brain metastases. One patient with alveolar soft part sarcoma and one patient with MPH died 24 and 16 months after craniotomy, respectively, and one patient with MPH committed suicide 4 months after craniotomy (mean survival, 14.7 months). All of them showed marked improvement of neurological symptoms and no evidence of recurrent brain tumors until their death. Five patients underwent external beam radiotherapy consisting of 30-55 Gy and their survival ranged from 1 to 8 months (mean, 3.8 months). Two of those four patients showed improved neurological symptoms and died of systemic problems and three patients died of brain metastasis. Thirteen patients received palliative steroid treatment with or without chemotherapy.Their survival ranged from 2 weeks to 8 months (mean, 2.7 months). Twelve of 13 patients died of systemic problems and one patient died of a neurological cause.
In all patients, the mean survival after diagnosis of brain metastasis was 5.1 months.
DISCUSSION
There have been a few reports of series studying the incidence of cerebral metastasis of sarcomas ranging from 1.6 to 10% (1,2) . However, these series included uterine, gastrointestinal and nasopharyngeal sarcomas. The true incidence of brain metastasis in sarcoma patients who present to orthopedic surgeons has not been well understood. Of 480 patients with sarcomas whom we reviewed, 20 (4.2%) developed brain metastases. In addition, it should be noted that among the advanced cases with distant metastases, over 10% had brain metastases.
Although it is well known that two thirds of all brain metastases are multiple (3), only eight of20 cases were multiple in this series. Bouffet et al. (4) also reported that only three of seven sarcoma patients with brain metastases had multiple lesions.
Three of four alveolar soft tissue sarcomas developed brain metastases. Comparing our cases with the reports in the literature, this tumor most frequently metastasizes to the brain in sarcomas (2, 5) . The tumor sometimes presents with lung or brain metastases, which are the first manifestation of the disease (6) . Skeletal metastasis, which is also rare in sarcomas, is frequent in this tumor (7) . Therefore, special attention should be paid to the brain and skeletal metastases in patients with alveolar soft part sarcoma.
Various reports suggest that Ewing's sarcoma and rhabdomyosarcoma also tend to metastasize to the brain, as in our series. The introduction of effective chemotherapy for these tumors has resulted in prolonged survival and an increased incidence of intracranial metastasis (1,2,4) .
Five patients withMFH was the largest number in this series. In other types of sarcomas, there seem to be no common histological types in brain metastasis. Probably almost all types of high-grade sarcomas can metastasize to the brain (1) .
As in previous reports, all patients in this study had distant or local relapses, especially in the lung (1, 4, 5) . When the patients have or had pulmonary metastases, the clinician should consider the possibility of brain metastasis.
Because most patients in this series had disseminated disease, the overall prognosis was poor. However, two of three patients who underwent total removal of the tumor survived over 1 year. Some reports indicate that complete removal of brain metastases for selected patients is associated with favorable prognosis (8, 9) . Of the 25 patients surgically treated in Wronski et al.'s series (8) , six survived over 20 months. In particular, surgical treatment for alveolar soft part sarcoma can result in a good prognosis (8).
Table2. Clinical summary of 20 patients with sarcoma metastatic to the brain
